Luye Pharma Group Ltd.
🇨🇳China
Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT04638491
- Locations
- 🇨🇳
Jilin Provincial Tumor Hospital, Changchun, Jilin, China
A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04630860
- Locations
- 🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, China
A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT04629404
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, China
A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04627155
to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04593511
- Locations
- 🇦🇺
CMAX clinical Research Pty Ltd, Adelaide, South Australia, Australia
Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04572685
- Locations
- 🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States
A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 416
- Registration Number
- NCT04572698
A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 294
- Registration Number
- NCT04571164
- Locations
- 🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, China
Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 290
- Registration Number
- NCT04563936
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT04384666
- Locations
- 🇺🇸
Pharmaceutical Research Associates, Inc., Salt Lake City, Utah, United States
© Copyright 2024. All Rights Reserved by MedPath